nach oben

Osteoporosis International

Erschienen in:

01.05.2007 | Editorial

Unmet needs in fracture prevention: new European guidelines for the investigation and registration of therapeutic agents

verfasst von: E. Seeman

Erschienen in: Osteoporosis International | Ausgabe 5/2007

Einloggen, um Zugang zu erhalten

Excerpt

Recognition of the problem of age-related bone fragility emerged in the middle of the last century when Fuller Albright drew attention to the common occurrence of vertebral fractures in postmenopausal women [1]. With increasing numbers of individuals living into old age, hip fractures gained recognition because of the high incidence, morbidity, mortality and cost imposed by this type of fracture [2]. …

Albright F, Smith PH, Richardson AM (1941) Postmenopausal osteoporosis. JAMA 116:2465–2474

Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby AK (2003) The components of excess mortality after hip fracture. Bone 32:468–473, Kanis JA, Johnell O, Oden A, De Laet C, Jonsson B, Dawson A. Ten year risk of osteoporotic fracture and the effect of risk factors on screening strategies. Bone 2002;30:251–8PubMedCrossRef

Melton LJ, Gabriel SE, Crowson CS, Tosteson ANA, Johnell O, Kanis JA (2003) Cost equivalence of different osteoporotic fractures. Osteoporosis International 14:383–388PubMedCrossRef

Kanis JA, Oden A, Johnell O, Jonsson B, de Laet C, Dawson A (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporosis International 12:417–427PubMedCrossRef

Siris ES, Chen YT, Abbott TA, Barrett-Connor E, Miller PD, Wehren LE, Berger ML (2004) Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 164:1108–1112PubMedCrossRef

Sanders K, Nicholson G, Watts J et al (2006) Half the burden of fragility fractures in the community occur in women without osteoporosis. When is fracture prevention cost effective? Bone 38:694–700PubMedCrossRef

Sornay-Rendu E, Munoz F, Garnero P, Duboeuf F, Delmas PD (2005) The identification of osteopenic women at high risk of fracture: the OFELY Study. J Bone Miner Res 20:1929–1934PubMedCrossRef

Population Division of the Department of Economic and Social Affairs of the Nations Secretariat 2002 World Population Prospects: The 2002 Revision and World Urban Prospects. Online http://esa.un.org/unpp. Accessed January 2006

Seeman E, Bianchi G, Khosla S, Kanis JA, Orwoll E (2006) Bone fragility in men-where are we? Osteoporos Int 17:1577–1583PubMedCrossRef

10.

Compston JE, Seeman E (2006) Compliance with osteoporosis therapy is the weakest link. Lancet 368:973–974PubMedCrossRef

11.

Delmas PD (2002) Treatment of postmenopausal osteoporosis. Lancet 359:2018–2026PubMedCrossRef

12.

Black DM, Boonen S, Cauley J et al (2006) Effect of once-yearly infusion of zoledronic acid 5 mg on spine and hip fracture reduction in postmenopausal women with osteoporosis: the HORIZON pivotal fracture trial. J Bone Mineral Res 21(suppl 1):s1–s530[1054]

13.

Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, Devogelaer JP, Curiel MD, Sawicki A, Goemaere S, Sorensen OH, Felsenberg D, Meunier PJ (2005) Strontium ranelate reduces the risk of non vertebral fractures in postmenopausal women with osteoporosis: TReatment Of Peripheral OSsteoporosis (TROPOS) Study. J Clin Endoc Metab 90:2816–2822CrossRef

14.

Sato Y, Iwamoto J, Kanoko T, Satoh K (2005) Risedronate therapy for prevention of hip fracture after stroke in elderly women. Neurology 64:811–816PubMed

15.

Sato Y, Kanoko T, Satoh K, Iwamoto J (2005) The prevention of hip fracture with risedronate and ergocalciferol plus calcium supplementation in elderly women with Alzheimers Disease. A randomized controlled trial. Arch Intern Med 165:1737–1742PubMedCrossRef

16.

Sato Y, Iwanmoto J, Kanok T, Satoh K (2005) Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke. Arch Intern Med 165:1743–1748PubMedCrossRef

17.

Black DM, Thompson DE, Bauer DC et al (2000) FIT Re-search Group. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. J Clin Endocrinol Metab 85:4118–4124PubMedCrossRef

18.

Jackson RD, LaCroix AZ, Gass M et al (2006) for the Women’s Health Initiative Investigators. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 354:669–683PubMedCrossRef

19.

Prince RL, Devine A, Dhaliwal SS, Dick IM (2006) Effects of calcium supplementation on clinical fracture and bone structure results of a 5-year, double-blind, placebo-controlled trial in elderly women. Arch Intern Med 166:869–875PubMedCrossRef

20.

Reid IR, Mason B, Horne A, Ames R, Reid HE, Bava U, Bolland MJ, Gamble GD (2006) Randomized controlled trial of calcium in healthy older women Amer J Med 119:777–785PubMedCrossRef

21.

Kanis JA, Johnell O, Black DM et al (2003) Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial. Bone 33:293–300PubMedCrossRef

22.

Seeman E, Devogelaer JP, Lorenc RS, Spector T, Brixen K, Vellas B, Balogh A, Stucki G, Meunier PJ, Reginster JY (2004) Strontium ranelate: the first anti-osteoporotic agent to reduce the risk of vertebral fracture in patients with lumbar osteopenia. IOF World Congress on Osteoporosis, Rio de Janeiro, 14–18, May, OC45

23.

Quandt SA, Thompson DE, Schneider DL et al (2005) Fracture Intervention Trial Research Group. Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of −1.6 to −2.5 at the femoral neck: the Fracture Intervention Trial. Mayo Clin Proc 80:343–349PubMedCrossRef

24.

Laupacis A, Sackett DL, Roberts RS (1988) An assessment of clinically useful measures of the consequences of treatment. New Engl J Med 318:1728–1733PubMedCrossRef

25.

Boonen S, McClung MR, Eastell R, Fuleihan GE-H, Barton IP, Delmas PD (2004) Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest Old. JAGS 52:1832–1839CrossRef

26.

Boonen S, Marin F, Mellstrom M, Xie L, Desaiah D, Krege JH, Rosen CJ (2006) Safety and efficacy of teriparatide in elderly women with established osteoporosis: Bone anabolic therapy from a geriatric Perspective. JAGS

27.

Seeman E, Vellas B, Benhamou C, Aquino JP, Semler J, Kaufman JM, Hoszowski, RoceVarel AR, Fiore C, Brixen K, Reginster JY, Boonen S (2006) Strontium ranelate reduces the risk of vertebral and non-vertebral fractures in women aged eighty years and over. J Bone Miner Res 21:1113–1120PubMedCrossRef

28.

Guyatt GH, Crabbey A, Griffith L, Walters S, Krolicki N, Favus M, Rosen C (2002) Summary of meta analyses of therapies for postmenopausal osteoporosis and the relationship between bone density and fractures. Endocrinol Metab Clin North Am 31:656–670CrossRef

29.

Kanis JA, Oden A, Hohnell O, Caulin F, Bone H, Alexandre JM, Abadie E, Lekkerkerker F (2002) Uncertain future of trials in osteoporosis. Osteoporos Int 13:443–449PubMedCrossRef

30.

Reginster J-Y, Abadie E, Delmas PD, Rizzoli R, Dere W, der Auwera P, Avouac B, Brandi ML, Daifotis A, Diez-Perez A, Calvo G, Johnell O, Kaufman J-M, Kreutz G, Laslop A, Lekkerkerker F, Mitlak B, Nilsson P, Orloff J, Smillie M, Taylor A, Tsouderos Y, Ethgen D, Flamion B (2006) Recommendations for an update of the current (2001) regulatory requirements for registration of drugs to be used in the treatment of osteoporosis in postmenopausal women and in men. Osteoporos Int 17:1–7PubMedCrossRef

31.

Committee for medicinal products for human use (CHMP). Guidelines on the evaluation of medicinal products in the treatment of primary osteoporosis. Lond 16 Nov 2006 CPMP/EWP/552/95 Rev.2

32.

Delmas PD, Seeman E (2004) Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy. Bone 34:599–604PubMedCrossRef

33.

Bauer DC, Garnero P, Hochberg MC, Santora A, Delmas P, Ewing SK, Black DM (2006) Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. J Bone Miner Res 21:292–299PubMedCrossRef

34.

Perel P, Roberts I, Sena E, Wheble P, Briscoe C, Sandercock P, Macleod M, Mignini LE, Jayaram P, Khan KS (2006) Comparison of treatment effects between animal experiments and clinical trials: systematic review. BMJ. Dec 15 on line DOI 10.1136/bmj.39048.407928.BE

35.

Concato J, Shah N, Horwitz RI (2000) Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 342:1887–1892PubMedCrossRef

36.

Writing Group for the Women’s Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomised controlled trial. JAMA 288:321–333CrossRef

37.

Seeman E, Delmas PD (2006) Bone Quality; the material and structural basis of bone strength. N Engl J Med 354:2250–2261PubMedCrossRef

38.

Black DM, Schwarz AW, Ensrud KE et al (2006) Effects of continuing or stopping alendronate after 5 years of treatment. JAMA 296:2927–2938PubMedCrossRef

39.

Prince R, Sipos A, Hossain A, Syversen U, Ish-Shalom S, Marcinowska E, Halse J, Lindsay R, Dalsky GP, Mitlak BM (2005) Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res 20:1507–1513PubMedCrossRef

40.

Mellstrom DD, Sorensen OH, Goemaere S, Roux C, Johnson TD, Chines AA (2004) Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 75:462–468PubMedCrossRef

41.

Bone HG, Hosking D, Devogelaer J-P, Tucci JR, Emkey RD, Yonino RP, RodriguezPortales JA, Downs RW, Gupta J, ACSantora, Liberman UA (2004) Ten years experience with alendronate for osteoporosis in postmenopausal women. N Eng J Med 350:1189–1199CrossRef

42.

Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB (2000) Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 15:613–620PubMedCrossRef

43.

Odvina CV, Zerwekh JE, Rao DS, Maaloof N, Gottschalk FA, Pak CYC (2005) Severly suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 1294–1301

44.

Bilezikian JP (2006) Osteonecrosis of the jaw–do bisphosphonates pose a risk? N Engl J Med 30;355:2278–2281CrossRef

45.

Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S (2003) Brief report: bisphosphonare-dinduced osteopetrosis. New Engl J Med 349:457–463PubMedCrossRef

46.

Seeman E, Compston J. Adachi J, Brandi ML, Cooper C, Dawson-Hughes B, Jönsson B, Pols H, Cramer JA. Non-compliance: the Achilles’ heel of anti-fracture efficacy. In press Osteoporosis Int

47.

Boutroy S, Bouxsein ML, Munoz F, Delmas PDD (2005) In vivo assessment of trabecular microarchitecture by high-resolution peripheral quantitative computed tomography. J Clin Endocriol Metab 90:6508–6515CrossRef

48.

Bouxsein ML, Melton LJ, Riggs BL, Muller J, Atkinson EJ, Oberg AL, Robb RA, Camp JJ, Rouleau PA, McCollough CH, Khosla S (2006) Age- and sex-specific differences in the factor of risk for vertebral fracture: a population-based study using QCT. J Bone Miner Res 21:1475–1482PubMedCrossRef

49.

Johnell O, Kanis JA (2006) An estimate of the world-wide prevalence and disability associated with osteoporotic fractures. Osteoporosis International 17:1726–1733PubMedCrossRef

50.

Garnero P, Delmas PD (2004) Contribution of bone mineral density and bone turnover markers to the estimation of risk of osteoporotic fracture in postmenopausal women. J Musculoskel Neiuron Interact 4:50–63

51.

Martin TJ, Seeman E (2006) New mechanisms and targets in the treatment of bone fragility. Clin Science 112:77–91

52.

McClung MR, Lewiecki EM, Cohen SB et al (2006) Denosumab in postmenopausal women with low bone mineral density. New Engl J Med 354:821–831PubMedCrossRef

53.

Adami S, Supronik J, Hala T et al (2006) Effect of one year treatment with the Cathepsin-K Inhibitor, Balicatib, on bone mineral density (BMD) in postmenopausal women with osteopenia/osteoporosis. J Bone Mineral Res 21(suppl 1):s1–s530[1085]

54.

Papanastasiou P, Ortmann CE, Olson M et al (2006) Effect of Three Month Treatment with the cathepsin-K inhibitor, balicatib, on biochemical markers of bone turnover in postmenopausal women: evidence for uncoupling of bone resorption and bone formation. J Bone Mineral Res 21(suppl 1):s1–s530[1223]

55.

Rose G (2001) Sick individuals and sick populations. Int J Epidemiol 30:427–432PubMedCrossRef

56.

Kronhed A-C G, Blomberg C, Karlsson N, Lofman O, Tmpka T, Moller M (2005) Impact of a community-based osteoporosis and fall prevention program on fracture incidence. Osteoporos Int 16:700–706CrossRef

57.

Melton LJ, Atkinson EJ, Madbok R (1996) Downturn in hip fracture incidence. Public Health Reports 111:146–150PubMed

58.

Newman ED, Ayoub WT, Starkey RH, Diehl JM, Wood GC (2003) Osteoporosis disease management in a rural health care population: hip fracture reduction and reduced costs in postmenopausal women after 5 years. Osteoporos Int 14:146–151PubMed

59.

Melton LJ, Kanis JA, Johnell O (2005) Potential impact of osteoporosis treatment on hip fracture trends. J Bone Miner Res 20:895–897PubMedCrossRef

60.

Eliot TS, The Wasteland

Titel: Unmet needs in fracture prevention: new European guidelines for the investigation and registration of therapeutic agents
verfasst von: E. Seeman
Publikationsdatum: 01.05.2007
Verlag: Springer-Verlag
Erschienen in: Osteoporosis International / Ausgabe 5/2007
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-007-0350-z

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen.
» Jetzt entdecken

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Arthroskopie kann Knieprothese nicht hinauszögern

25.04.2024 Gonarthrose Nachrichten

Ein arthroskopischer Eingriff bei Kniearthrose macht im Hinblick darauf, ob und wann ein Gelenkersatz fällig wird, offenbar keinen Unterschied.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Ärztliche Empathie hilft gegen Rückenschmerzen

23.04.2024 Leitsymptom Rückenschmerzen Nachrichten

Personen mit chronischen Rückenschmerzen, die von einfühlsamen Ärzten und Ärztinnen betreut werden, berichten über weniger Beschwerden und eine bessere Lebensqualität.

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2007

Trends in hospital care for hip fractures

High bone mineral density in pycnodysostotic patients with a novel mutation in the propeptide of cathepsin K

Alcohol consumption, bone density, and hip fracture among older adults: the cardiovascular health study

Calcium-PTH-vitamin D axis in older patients with hip fracture

The clinical utility of measured kyphosis as a predictor of the presence of vertebral deformities